Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, April 2009, p. 1539-1545, Vol. 53, No. 4
0066-4804/09/$08.00+0 doi:10.1128/AAC.00961-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.
Roles of NF-
B Activation and Peroxisome Proliferator-Activated Receptor Gamma Inhibition in the Effect of Rifampin on Inducible Nitric Oxide Synthase Transcription in Human Lung Epithelial Cells
Yael Yuhas,1,4*
Eva Berent,1
Regev Cohen,3 and
Shai Ashkenazi1,2,4
Laboratory of Infectious Diseases, Felsenstein Medical Research Center,1 Department of Pediatrics A, Schneider Children's Medical Center of Israel,2 Department of Internal Medicine, Rabin Medical Center, Petach Tikva,3 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel4
Received 20 July 2008/ Returned for modification 10 September 2008/ Accepted 19 December 2008
Rifampin (rifampicin), an important antibiotic agent and a major drug used for the treatment of tuberculosis, exerts immunomodulatory effects. Previous studies have found that rifampin increases inducible nitric oxide (NO) synthase (iNOS) expression and NO production. The present study investigated the potential mechanism(s) underlying these actions. The incubation of human lung epithelial A549 cells with a cytokine mix (interleukin-1β, tumor necrosis factor alpha, and gamma interferon) induced the expression of iNOS mRNA. The addition of rifampin increased the iNOS level by 1.9 ± 0.3-fold at a dose of 10 µg/ml (P < 0.01) and by 4.0 ± 0.3-fold at a dose of 50 µg/ml (P < 0.001). Rifampin treatment also affected the transcription factors that regulate iNOS mRNA: there was an increased and prolonged degradation of the inhibitory subunit of NF-
B, a corresponding increase in the level of cytokine-induced DNA binding of NF-B (2.1 ± 0.2-fold), and a decrease in the level of expression of peroxisome proliferator-activated receptor gamma (PPAR
). Specifically, the level of PPAR expression dropped by 15% in response to cytokine stimulation and by an additional 40% when rifampin was added (P < 0.001). Rifampin had no effect on the activation of mitogen-activated protein kinases or the signal transducer and transcription activator (STAT-1). In conclusion, rifampin augments NO production by upregulating iNOS mRNA. It also increases the level of NF-B activation and decreases the level of PPAR expression. The increases in the levels of NF-B activation and NO production probably contribute to the therapeutic effects of rifampin. However, given the role of NF-B in upregulating many inflammatory genes and the roles of PPAR in downregulating inflammatory genes and in lipid and glucose metabolism, these findings have implications for potential adverse effects of rifampin in patients with chronic inflammatory diseases and glucose or lipid disorders.
* Corresponding author. Mailing address: Laboratory of Infectious Diseases, Felsenstein Medical Research Center, Beilinson Campus, Petach Tikva 49100, Israel. Phone: 972-3-9376736. Fax: 972-3-9253056. E-mail: yuhas{at}post.tau.ac.il
Published ahead of print on 29 December 2008.
Antimicrobial Agents and Chemotherapy, April 2009, p. 1539-1545, Vol. 53, No. 4
0066-4804/09/$08.00+0 doi:10.1128/AAC.00961-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»